Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170338 | 0.88 | SLC6A4 (0.49) | TAAR1SIGMAR1HTR2ASLC6A2SLC6A4 | |
| SCHEMBL20408267 | 0.86 | SIGMAR1 (0.53) | TAAR1SIGMAR1HTR2ASLC6A2SLC6A4 | |
| SCHEMBL4710713 | 0.83 | HTR2A (0.51) | TAAR1SIGMAR1HTR2AHTR1AHTR2C | |
| SCHEMBL11318718 | 0.79 | TAAR1 (0.46) | TAAR1SIGMAR1HTR2AHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL11154623 | 0.79 | SIGMAR1 (0.48) | TAAR1SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL234864 | 0.78 | CYP3A4 (0.53) | TAAR1SIGMAR1 | |
| SCHEMBL27759121 | 0.77 | SIGMAR1 (0.47) | SIGMAR1AOC3 | |
| SCHEMBL4313605 | 0.77 | SLC6A4 (0.63) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3060544 | 0.76 | TAAR1 (0.61) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL3064919 | 0.76 | TAAR1 (0.61) | TAAR1HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103153063-A | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE INC | 2013-06-12 | — | — | CN | disclosed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-101272685-A | Diarylamine-containing compounds and compositions, and their use as modulators of C-KIT receptors | IRM LLC (BM) | 2008-09-24 | — | — | CN | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-5972937-A | Heterocyclic compounds possessing 5HT2C receptor antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0807104-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT 2C? RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023769-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
| US-4333930-A | TREATMENT OF CENTRAL NERVOUS DISORDERS, ANALGESICS, ANTIDEPRESSANTS | LABORATOIRES SARGET (FR) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | TAAR1 871/4885SIGMAR1 905/4885HTR2A 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.